Resource Type

Journal Article 152

Year

2023 14

2022 20

2021 9

2020 11

2019 14

2018 7

2017 9

2016 7

2015 8

2014 6

2013 4

2012 10

2011 2

2010 5

2009 11

2008 4

2007 3

2000 1

1999 1

open ︾

Keywords

targeted therapy 8

cancer therapy 7

cancer 6

immunotherapy 6

therapy 6

gene therapy 5

hepatocellular carcinoma 4

COVID-19 2

angiogenesis 2

boron neutron capture therapy 2

cancer immunotherapy 2

clinical trial 2

drug resistance 2

molecular classification 2

prevention 2

radiation therapy 2

traditional Chinese medicine 2

3-dimensional conformal radiation therapy 1

ALK fusion 1

open ︾

Search scope:

排序： Display mode:

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Frontiers of Medicine 2009, Volume 3, Issue 3,   Pages 245-255 doi: 10.1007/s11684-009-0044-3

Abstract: The early diagnosis and therapy of lung cancer still presents a big challenge because validated screeningTherefore, this information may be applied for early cancer detection, classification, novel targetedtherapy, and prognosis in NSCLC.Recent clinical data have revealed that targeted therapy might be the second-line therapy as an alternativethat we can further identify effectiveness of targeted therapy in the future.

Keywords： lung cancer     carcinoma     non-small cell lung cancer     molecular markers     targeted therapy    

HTML PDF Collect

Molecular classification and molecular targeted therapy of cancer

Miao Xu, Jianyong Shao, Yixin Zeng

Frontiers of Medicine 2013, Volume 7, Issue 2,   Pages 147-149 doi: 10.1007/s11684-013-0274-2

HTML PDF Collect

mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?

Shi-Yong Sun

Frontiers of Medicine 2021, Volume 15, Issue 2,   Pages 221-231 doi: 10.1007/s11684-020-0812-7

Abstract: scientific rationale, the intriguing question is why cancers are insensitive or not responsive to mTOR-targetedcancer therapy in clinics.ERK, and Mnk/eIF4E survival signaling pathways that compromise the efficacy of rapalog-based cancer therapyThese new findings may also offer us the opportunity to rationally utilize mTOR inhibitors in cancer therapy

Keywords： mTOR     cancer therapy     resistance     GSK3     protein degradation     E3 ubiquitin ligase     PD-L1    

HTML PDF Collect

Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects

Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao

Frontiers of Medicine 2019, Volume 13, Issue 4,   Pages 427-437 doi: 10.1007/s11684-018-0672-6

Abstract: Tyrosine kinase and γ-secretase inhibitors are primarily used in the targeted therapy of DF.Previous studies that focused on the mechanism, efficacy, and safety of targeted therapy for DF wereThe efficacy and safety of targeted therapy were compared with those of other systemic therapy optionsTargeted therapy does not provide considerable advantages in efficacy and safety over other medical treatmentstherapy of DF.

Keywords： targeted therapy     desmoid-type fibromatosis     tyrosine kinase inhibitor     γ-secretase inhibitor    

HTML PDF Collect

Progress and challenges in RET-targeted cancer therapy

Frontiers of Medicine 2023, Volume 17, Issue 2,   Pages 207-219 doi: 10.1007/s11684-023-0985-y

Abstract: The rearranged during transfection (RET) is a receptor protein tyrosine kinase. Oncogenic RET fusions or mutations are found most often in non-small cell lung cancer (NSCLC) and in thyroid cancer, but also increasingly in various types of cancers at low rates. In the last few years, two potent and selective RET protein tyrosine kinase inhibitors (TKIs), pralsetinib (BLU-667) and selpercatinib (LOXO-292, LY3527723) were developed and received regulatory approval. Although pralsetinib and selpercatinib gave high overall response rates (ORRs), < 10% of patients achieved a complete response (CR). The RET TKI-tolerated residual tumors inevitably develop resistance by secondary target mutations, acquired alternative oncogenes, or MET amplification. RET G810 mutations located at the kinase solvent front site were identified as the major on-target mechanism of acquired resistance to both selpercatinib and pralsetinib. Several next-generation of RET TKIs capable of inhibiting the selpercatinib/pralsetinib-resistant RET mutants have progressed to clinical trials. However, it is likely that new TKI-adapted RET mutations will emerge to cause resistance to these next-generation of RET TKIs. Solving the problem requires a better understanding of the multiple mechanisms that support the RET TKI-tolerated persisters to identify a converging point of vulnerability to devise an effective co-treatment to eliminate the residual tumors.

Keywords： pralsetinib     selpercatinib     RET-alteration     lung cancer     thyroid cancer     tumor-agnostic therapy     drug    

HTML PDF Collect

Synthesis and application of superparamagnetic iron oxide nanoparticles in targeted therapy and imaging

Liangqian Tong, Ming Zhao, Shu Zhu, Jing Chen

Frontiers of Medicine 2011, Volume 5, Issue 4,   Pages 379-387 doi: 10.1007/s11684-011-0162-6

Abstract: studies have shown the exciting potential of functionalized SPIO nanoparticles, such as surface-coated, targetedligand-conjugated, and/or drug-loaded SPIO nanoparticles, as powerful tools for targeted imaging andtherapy.Moreover, the applications of SPIO nanoparticles that integrate diagnosis and therapy in SPIO nanoparticlestherapy, and cancer imaging.

Keywords： nanoparticles     superparamagnetic iron oxide     targeted therapy     molecular imaging     cancer    

HTML PDF Collect

Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy

Frontiers of Medicine 2023, Volume 17, Issue 3,   Pages 493-502 doi: 10.1007/s11684-022-0946-x

Abstract: heterogeneity (ITH) has been proven to contribute to the poor treatment response and the resistance to targetedwhether the variant allele frequencies (VAFs) of ALK fusions can help assess ITH and predict targetedtherapy efficacy.ALK VAF determined by hybrid capture-based NGS is probably unreliable for ITH assessment and targetedtherapy efficacy prediction in NSCLC.

Keywords： situ hybridization     immunohistochemistry     variant allele frequency     intratumoral heterogeneity     targetedtherapy    

HTML PDF Collect

Molecular targeted therapy of gynecological malignant tumors: the development and challenge, from laboratory

Pengming SUN PhD, MD , Jalid SEHOULI PhD, MD , Lihui WEI BM ,

Frontiers of Medicine 2009, Volume 3, Issue 3,   Pages 256-264 doi: 10.1007/s11684-009-0052-3

Abstract: More and more molecular drugs based on targeted therapy have been utilized in the treatment of gynecologicIn this article, we systematically review the current targeted therapeutic trials running in clinic.in gynecological carcinogenesis andprogression suggest that combination chemotherapy with molecular targetedtherapy will ultimately be an importantoption.

Keywords： target therapy     gynecologic malignant tumors     clinical trail     molecular medicine    

HTML PDF Collect

Progress in systemic therapy for triple-negative breast cancer

Hongnan Mo, Binghe Xu

Frontiers of Medicine 2021, Volume 15, Issue 1,   Pages 1-10 doi: 10.1007/s11684-020-0741-5

Abstract: treatment strategies, including modified chemotherapy approaches, immune checkpoint inhibitors, and targeted

Keywords： triple-negative breast cancer     immunotherapy     targeted therapy    

HTML PDF Collect

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 689-700 doi: 10.1007/s11684-020-0759-8

Abstract: in outcome will need to rely more heavily on molecular therapeutic as well as immuno- and cellular-therapyThere are other fusions or mutations that may serve as putative targets, but effective targeted therapygenetic lesions, current approaches that offer hope include blinatumomab, inotuzumab and CAR-T cell therapyWith the expanding therapeutic armamentarium, we should start focus on rational combinations of targetedtherapy with non-overlapping toxicities.

Keywords： acute lymphoblastic leukemia     molecular therapeutics     targeted therapy     tyrosine kinase inhibitors     immunotherapy     CAR T-cell therapy    

HTML PDF Collect

Influence of Survivin-targeted siRNA on the biological features of colorectal carcinoma cells

XIONG Ying, GUO Wen, LI Ting, LI Ke

Frontiers of Medicine 2007, Volume 1, Issue 3,   Pages 304-307 doi: 10.1007/s11684-007-0058-7

Abstract: The transient transfection of survivin-targeted siRNA to Lovo cells and its influence on the biologicalTwo pairs of 19 base pairs (bp) siRNA-specific targeted survivin gene were designed and synthesized byAfter transient transfection of the two survivin-targeted siRNAs to Lovo cells by Lipofectamine™ 2000Based on the results, we can draw a conclusion that the two survivin-targeted siRNAs successfully suppressedIt provides a powerful evidence for colorectal carcinoma gene therapy.

Keywords： control     therapy     influence     Survivin-1     colorectal carcinoma    

HTML PDF Collect

Platelet membrane-based and tumor-associated platelet- targeted drug delivery systems for cancer therapy

Yinlong Zhang, Guangna Liu, Jingyan Wei, Guangjun Nie

Frontiers of Medicine 2018, Volume 12, Issue 6,   Pages 667-677 doi: 10.1007/s11684-017-0583-y

Abstract: membrane-based drug delivery and unique strategies that target tumor-associated platelets for cancer therapy

Keywords： platelet-mimicking delivery systems     tumor-associated platelets     cancer therapy     EPR effect    

HTML PDF Collect

Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor

Wenjie Zhu, Binghe Xu

Frontiers of Medicine 2021, Volume 15, Issue 2,   Pages 208-220 doi: 10.1007/s11684-020-0795-4

Abstract: New targeted therapies have been developed to overcome resistance to endocrine therapy (ET) and improveWe conducted a meta-analysis and systemic review on randomized controlled trials evaluating various targeted

Keywords： endocrine-resistant     HR+/HER2- advanced breast cancer     randomized clinical trials     meta-analysis     targetedtherapy    

HTML PDF Collect

Taking advantage of drug resistance, a new approach in the war on cancer

Liqin Wang, Rene Bernards

Frontiers of Medicine 2018, Volume 12, Issue 4,   Pages 490-495 doi: 10.1007/s11684-018-0647-7

Abstract: of the driver mutations in cancer has resulted in the development of a new category of molecularly targetedWe discuss the development of sequential drug therapies in which the first therapy is not given withcurative intent, but to induce a major new sensitivity that can be targeted with a second drug that selectivelyhas hitherto not been used on a large scale in the clinic and holds great promise for future cancer therapy

Keywords： cancer     drug resistance     genetic screens     senescence     targeted therapy    

HTML PDF Collect

Studies on preparation of folate-targeted boron liposomes as potential delivery agents for neutron capture

Wang Zhihui,Qin Linxue,Liu Dong

Strategic Study of CAE 2012, Volume 14, Issue 8,   Pages 78-81

Abstract:

To prepare folate-targeted liposomes with high encapsulation efficiencyis an effective targeted drug delivery agent for boron neutron capture therapy (BNCT).efficiency for BBA liposomes in the optimal groups reached 94.8 %.The technique of preparing folate-targeted

Keywords： boron neutron capture therapy     liposomes     folate-targeted     encapsulation efficiency    

HTML PDF Collect

Title Author Date Type Operation

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Journal Article

Molecular classification and molecular targeted therapy of cancer

Miao Xu, Jianyong Shao, Yixin Zeng

Journal Article

mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?

Shi-Yong Sun

Journal Article

Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects

Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao

Journal Article

Progress and challenges in RET-targeted cancer therapy

Journal Article

Synthesis and application of superparamagnetic iron oxide nanoparticles in targeted therapy and imaging

Liangqian Tong, Ming Zhao, Shu Zhu, Jing Chen

Journal Article

Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy

Journal Article

Molecular targeted therapy of gynecological malignant tumors: the development and challenge, from laboratory

Pengming SUN PhD, MD , Jalid SEHOULI PhD, MD , Lihui WEI BM ,

Journal Article

Progress in systemic therapy for triple-negative breast cancer

Hongnan Mo, Binghe Xu

Journal Article

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Journal Article

Influence of Survivin-targeted siRNA on the biological features of colorectal carcinoma cells

XIONG Ying, GUO Wen, LI Ting, LI Ke

Journal Article

Platelet membrane-based and tumor-associated platelet- targeted drug delivery systems for cancer therapy

Yinlong Zhang, Guangna Liu, Jingyan Wei, Guangjun Nie

Journal Article

Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor

Wenjie Zhu, Binghe Xu

Journal Article

Taking advantage of drug resistance, a new approach in the war on cancer

Liqin Wang, Rene Bernards

Journal Article

Studies on preparation of folate-targeted boron liposomes as potential delivery agents for neutron capture

Wang Zhihui,Qin Linxue,Liu Dong

Journal Article